Drug Approval | October 18, 2021
U.S. FDA approves Roche’s Tecentriq as adjuvant treatment for small cell lung cancer
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
Tecentriq is the first and only cancer immunotherapy approved for NSCLC in the adjuvant setting
The injection is used to reverse the effects of the muscle relaxants given to patients during surgery
The transaction is anticipated to close in the first quarter of 2022
These aprons utilise phase change materials that absorb, store and release heat for optimal thermal comfort
The recipient is a 57-year-old woman who was suffering from severe biventricular heart failure and had undergone cardiac surgery several years ago
The approval will enable the treatment of patients in India living with Essential tremor, tremor-dominant Parkinson's Disease and neuropathic pain
The trial will evaluate the efficacy of psilocybin in Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA). The data is expected in early 2022
In comparison to traditional open-heart surgery, which involves opening up the chest by splitting the breastbone, da Vinci Xi's innovative technology allows for complex cardiovascular surgeries to be performed through smaller incisions and precise motion control
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
The lab has been developed to aid surgeons to overcome the challenging learning curve to obtain laparoscopic expertise
Subscribe To Our Newsletter & Stay Updated
